ECSP099395A - Nuevos derivados de los ácidos amino-nicotínico y amino-isonicotínico - Google Patents
Nuevos derivados de los ácidos amino-nicotínico y amino-isonicotínicoInfo
- Publication number
- ECSP099395A ECSP099395A EC2009009395A ECSP099395A ECSP099395A EC SP099395 A ECSP099395 A EC SP099395A EC 2009009395 A EC2009009395 A EC 2009009395A EC SP099395 A ECSP099395 A EC SP099395A EC SP099395 A ECSP099395 A EC SP099395A
- Authority
- EC
- Ecuador
- Prior art keywords
- halogen atoms
- groups
- optionally substituted
- group
- substituents selected
- Prior art date
Links
- 239000002253 acid Substances 0.000 title 1
- 150000007513 acids Chemical class 0.000 title 1
- 125000005843 halogen group Chemical group 0.000 abstract 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 14
- 125000001424 substituent group Chemical group 0.000 abstract 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 150000001768 cations Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Un compuesto de fórmula (I) Formula (I)en donde:" uno de los grupos G1 representa un átomo de nitrógeno o un grupo CRc y el otro representa un grupo CRc" G2 representa un átomo de nitrógeno o un grupo CRd" R1 representa un grupo seleccionado de átomos de hidrógeno, átomos de halógeno, grupos alquilo C1-4 que pueden estar opcionalmente sustituidos con 1, 2 ó 3 sustituyentes seleccionados de átomos de halógeno y grupo hidroxi, y grupos cicloalquilo C3-8 que pueden estar opcionalmente sustituidos con 1, 2 ó 3 sustituyentes seleccionados de átomos de halógeno y grupo hidroxi" R2 representa un grupo seleccionado de átomos de hidrógeno, átomos de halógeno, grupos hidroxilo, grupos alquilo C1-4 que pueden estar opcionalmente sustituidos con 1, 2 ó 3 sustituyentes seleccionados de átomos de halógeno y grupo hidroxi, grupos alcoxi C1-4 que pueden estar opcionalmente sustituidos con 1, 2 ó 3 sustituyentes seleccionados de átomos de halógeno y grupo hidroxi, y grupos cicloalquilo C3-8 que pueden estar opcionalmente sustituidos con 1, 2 ó 3 sustituyentes seleccionados de átomos de halógeno y grupo hidroxi" Ra, Rb y Rc representan independientemente grupos seleccionado de átomos de hidrógeno, átomos de halógeno, grupos alquilo C1-4 que pueden estar opcionalmente sustituidos con 1, 2 ó 3 sustituyentes seleccionados de átomos de halógeno y grupo hidroxi, y grupos alcoxi C1-4 que pueden estar opcionalmente sustituidos con 1, 2 ó 3 sustituyentes seleccionados de átomos de halógeno y grupo hidroxi" Rd representa un grupo seleccionado de átomos de hidrógeno, átomos de halógeno, grupos hidroxilo, grupos alquilo C1-4 que pueden estar opcionalmente sustituidos con 1, 2 ó 3 sustituyentes seleccionados de átomos de halógeno y grupo hidroxi, y grupos alcoxi C1-4 que pueden estar opcionalmente sustituidos con 1, 2 ó 3 sustituyentes seleccionados de átomos de halógeno y grupo hidroxi, y grupos cicloalcoxi C3-8 que pueden estar opcionalmente sustituidos con 1, 2 ó 3 sustituyentes seleccionados de átomos de halógeno y grupo hidroxi" uno de los grupos G3 y G4 es un átomo de nitrógeno y el otro es un grupo CH, " M es un átomo de hidrógeno o un catión farmacéuticamente aceptable, con la condición de que, cuando al menos uno de los grupos Ra y Rb representa un átomo de hidrógeno y G2 es un grupo CRd, entonces Rd representa un grupo seleccionado de grupos alcoxi C1-4 que pueden estar opcionalmente sustituidos con 1, 2 ó 3 sustituyentes seleccionados de átomos de halógeno y grupo hidroxi, grupos cicloalcoxi C3-8 que pueden estar opcionalmente sustituidos con 1, 2 ó 3 sustituyentes seleccionados de átomos de halógeno y grupo hidroxi;y sus sales y N-óxidos farmacéuticamente aceptables.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200603250A ES2319596B1 (es) | 2006-12-22 | 2006-12-22 | Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico. |
| ES200701086A ES2327372B1 (es) | 2007-04-23 | 2007-04-23 | Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP099395A true ECSP099395A (es) | 2009-07-31 |
Family
ID=39319647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2009009395A ECSP099395A (es) | 2006-12-22 | 2009-06-09 | Nuevos derivados de los ácidos amino-nicotínico y amino-isonicotínico |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US8258308B2 (es) |
| EP (1) | EP2121614B1 (es) |
| JP (1) | JP5318776B2 (es) |
| KR (1) | KR101435233B1 (es) |
| CN (1) | CN101589025B (es) |
| AR (1) | AR064444A1 (es) |
| AU (1) | AU2007338321B2 (es) |
| BR (1) | BRPI0717697B1 (es) |
| CA (1) | CA2674512C (es) |
| CL (1) | CL2007003666A1 (es) |
| CY (1) | CY1113687T1 (es) |
| DK (1) | DK2121614T3 (es) |
| EC (1) | ECSP099395A (es) |
| ES (2) | ES2319596B1 (es) |
| HR (1) | HRP20120697T1 (es) |
| IL (1) | IL199188A (es) |
| ME (1) | ME01475B (es) |
| MX (1) | MX2009006408A (es) |
| MY (1) | MY153393A (es) |
| NO (1) | NO341991B1 (es) |
| NZ (1) | NZ577017A (es) |
| PE (1) | PE20081846A1 (es) |
| PL (1) | PL2121614T3 (es) |
| PT (1) | PT2121614E (es) |
| RS (1) | RS52514B (es) |
| RU (1) | RU2469024C2 (es) |
| SI (1) | SI2121614T1 (es) |
| TW (1) | TWI405572B (es) |
| UY (1) | UY30794A1 (es) |
| WO (1) | WO2008077639A1 (es) |
| ZA (1) | ZA200903335B (es) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| BRPI0711558A2 (pt) | 2006-05-04 | 2011-11-08 | Boeringer Ingelheim Internat Gmbh | polimorfos |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| ES2319596B1 (es) | 2006-12-22 | 2010-02-08 | Laboratorios Almirall S.A. | Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico. |
| ES2327372B1 (es) * | 2007-04-23 | 2010-08-24 | Laboratorios Almirall S.A. | Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico. |
| UY31272A1 (es) | 2007-08-10 | 2009-01-30 | Almirall Lab | Nuevos derivados de ácido azabifenilaminobenzoico |
| PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| EP2135610A1 (en) * | 2008-06-20 | 2009-12-23 | Laboratorios Almirall, S.A. | Combination comprising DHODH inhibitors and methotrexate |
| BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| KR20110093841A (ko) * | 2008-11-07 | 2011-08-18 | 4에스체 악티엔게젤샤프트 | 자가면역 질환의 치료를 위한 ｄｈｏｄｈ 억제제 및 메토트렉세이트를 포함하는 조합 요법 |
| EP2196465A1 (en) | 2008-12-15 | 2010-06-16 | Almirall, S.A. | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors |
| EP2226323A1 (en) | 2009-02-27 | 2010-09-08 | Almirall, S.A. | New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives |
| EP2228367A1 (en) | 2009-03-13 | 2010-09-15 | Almirall, S.A. | Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors |
| EP2239256A1 (en) | 2009-03-13 | 2010-10-13 | Almirall, S.A. | Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor |
| TWI530286B (zh) * | 2009-05-04 | 2016-04-21 | 帕納特斯製藥格斯有限公司 | 作為抑制病毒化合物之抗發炎劑 |
| EP2314577A1 (en) * | 2009-10-16 | 2011-04-27 | Almirall, S.A. | Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid |
| EA034869B1 (ru) | 2009-11-27 | 2020-03-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин |
| EP2338888A1 (en) | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Imidazopyridine derivatives as JAK inhibitors |
| UY33213A (es) | 2010-02-18 | 2011-09-30 | Almirall Sa | Derivados de pirazol como inhibidores de jak |
| EP2360158A1 (en) | 2010-02-18 | 2011-08-24 | Almirall, S.A. | Pyrazole derivatives as jak inhibitors |
| EP2380890A1 (en) | 2010-04-23 | 2011-10-26 | Almirall, S.A. | New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors |
| US8686048B2 (en) | 2010-05-06 | 2014-04-01 | Rhizen Pharmaceuticals Sa | Immunomodulator and anti-inflammatory compounds |
| EP2394998A1 (en) | 2010-05-31 | 2011-12-14 | Almirall, S.A. | 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors |
| EP2397482A1 (en) | 2010-06-15 | 2011-12-21 | Almirall, S.A. | Heteroaryl imidazolone derivatives as jak inhibitors |
| EP2441755A1 (en) | 2010-09-30 | 2012-04-18 | Almirall, S.A. | Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors |
| EP2444088A1 (en) | 2010-10-22 | 2012-04-25 | Almirall, S.A. | Amino derivatives for the treatment of proliferative skin disorders |
| EP2444086A1 (en) | 2010-10-22 | 2012-04-25 | Almirall, S.A. | Combinations comprising DHODH inhibitors and COX inhibitors |
| US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| EP2455080A1 (en) | 2010-11-23 | 2012-05-23 | Almirall, S.A. | S1P1 receptor agonists for use in the treatment of multiple sclerosis |
| EP2455081A1 (en) | 2010-11-23 | 2012-05-23 | Almirall, S.A. | S1P1 receptor agonists for use in the treatment of crohn's disease |
| EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
| EP2463289A1 (en) | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors |
| EP2672963A4 (en) | 2011-02-08 | 2015-06-24 | Childrens Medical Center | METHOD FOR THE TREATMENT OF MELANOMA |
| US10016402B2 (en) * | 2011-02-08 | 2018-07-10 | Children's Medical Center Corporation | Methods for treatment of melanoma |
| EP2489663A1 (en) | 2011-02-16 | 2012-08-22 | Almirall, S.A. | Compounds as syk kinase inhibitors |
| EP2518070A1 (en) | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Pyrrolotriazinone derivatives as PI3K inhibitors |
| EP2518071A1 (en) | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Imidazopyridine derivatives as PI3K inhibitors |
| EP2526945A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | New CRTH2 Antagonists |
| EP2527344A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases |
| EP2548876A1 (en) | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists |
| EP2548863A1 (en) | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists. |
| EP2554544A1 (en) | 2011-08-01 | 2013-02-06 | Almirall, S.A. | Pyridin-2(1h)-one derivatives as jak inhibitors |
| EP2594271A1 (en) | 2011-11-21 | 2013-05-22 | Almirall, S.A. | 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid for the treatment of psoriasis. |
| JP6224084B2 (ja) | 2012-05-14 | 2017-11-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体 |
| US20130303554A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in sirs and/or sepsis |
| WO2014060431A1 (en) | 2012-10-16 | 2014-04-24 | Almirall, S.A. | Pyrrolotriazinone derivatives as pi3k inhibitors |
| TWI638814B (zh) | 2012-10-31 | 2018-10-21 | 富山化學工業股份有限公司 | 新穎之胺衍生物或其鹽 |
| TW201446767A (zh) | 2013-02-15 | 2014-12-16 | Almirall Sa | 作為磷脂肌醇3-激酶抑製劑之吡咯並三嗪衍生物 |
| WO2015077535A2 (en) | 2013-11-22 | 2015-05-28 | Genzyme Corporation | Novel methods for treating neurodegenerative diseases |
| RU2016144238A (ru) | 2014-04-11 | 2018-05-11 | Паноптес Фарма Гмбх | Противовоспалительные средства в качестве вирусостатических соединений |
| JP6629840B2 (ja) * | 2014-05-08 | 2020-01-15 | パノプテス・ファーマ・ゲーエムベーハー | 眼の疾患および障害を処置するための化合物 |
| WO2016200778A1 (en) * | 2015-06-08 | 2016-12-15 | Children's Medical Center Corporation | Methods for treatment of melanoma |
| WO2016202800A1 (en) | 2015-06-16 | 2016-12-22 | Almirall, S.A. | Pyrrolotriazinone derivatives as pi3k inhibitors |
| CN109310697A (zh) | 2016-06-10 | 2019-02-05 | 勃林格殷格翰国际有限公司 | 利格列汀和二甲双胍的组合 |
| WO2018136010A1 (en) | 2017-01-20 | 2018-07-26 | Aslan Pharmaceuticals Pte Ltd | Combination therapy |
| WO2018136009A1 (en) | 2017-01-20 | 2018-07-26 | Aslan Pharmaceuticals Pte Ltd | Combination therapy |
| US11311548B2 (en) | 2017-03-02 | 2022-04-26 | Aslan Pharmaceuticals Pte. Ltd. | Cancer therapy |
| CN108530310B (zh) * | 2017-03-02 | 2025-01-28 | 中国科学院上海药物研究所 | 2-(取代苯杂基)芳香甲酸类fto抑制剂，其制备方法及其应用 |
| TW201834649A (zh) | 2017-03-02 | 2018-10-01 | 新加坡商亞獅康私人有限公司 | 癌症療法 |
| JP6978251B2 (ja) * | 2017-03-03 | 2021-12-08 | アスラン ファーマシューティカルズ ピーティーイー リミテッド | がん治療 |
| WO2018222135A1 (en) | 2017-06-02 | 2018-12-06 | Aslan Pharmaceuticals Pte Ltd | Cancer therapy |
| WO2018222134A1 (en) | 2017-06-02 | 2018-12-06 | Aslan Pharmaceuticals Pte Ltd | Cancer therapy |
| AU2019232153B2 (en) | 2018-03-09 | 2023-07-13 | Panoptes Pharma Ges.M.B.H. | Ophthalmic formulation |
| EP3858361B1 (en) | 2018-09-28 | 2025-10-08 | FUJIFILM Corporation | Antitumor agent containing cytarabine, antitumor effect enhancer used in combination with cytarabine, antitumor kit, and antitumor agent used in combination with cytarabine |
| WO2020130077A1 (ja) | 2018-12-21 | 2020-06-25 | 国立大学法人北海道大学 | 多能性幹細胞を除去するための組成物、及び多能性幹細胞の除去方法 |
| EP3750892A1 (en) | 2019-06-14 | 2020-12-16 | Yerevan State University | Novel 5-cyclopropyl-furo[3,4-c]pyridine-3,4(1h,5h)-dione 1,1' substituted derivatives and their uses |
| EP4052760B1 (en) * | 2019-10-31 | 2024-03-13 | FUJIFILM Corporation | Pyrazine derivative or salt thereof, and use of same |
| EP4190402B1 (en) * | 2020-07-30 | 2025-08-27 | FUJIFILM Corporation | Nitrogen-containing heterocyclic compound or salt thereof, use thereof, and intermediate thereof |
| US20230390276A1 (en) * | 2020-10-15 | 2023-12-07 | Aslan Pharmaceuticals Pte. Ltd. | Treatment of autoimmune diseases with a dihydroorotate hehydrogenase (dhodh) inhibitor |
| CN116940359A (zh) * | 2020-10-15 | 2023-10-24 | 亚狮康私人有限公司 | 用二氢乳清酸脱氢酶（dhodh）抑制剂治疗自身免疫病 |
| WO2023278778A1 (en) * | 2021-06-30 | 2023-01-05 | Ohio State Innovation Foundation | Methods and compositions for inhibition of dihydroorotate dehydrogenase in combination with an anti-cd47-sirpα therapeutic agent |
| WO2023147161A2 (en) * | 2022-01-31 | 2023-08-03 | New Frontier Bio, Inc. | Nicotinate and nicotinamide riboside-based compounds and derivatives thereof |
| WO2023149841A1 (en) * | 2022-02-03 | 2023-08-10 | Aslan Pharmaceuticals Pte Ltd | Dhodh inhibitor polymorph |
| JP2025513444A (ja) * | 2022-04-21 | 2025-04-24 | アスラン ファーマシューティカルズ ピーティーイー リミテッド | 自己免疫性皮膚疾患の治療 |
| WO2025215126A1 (en) | 2024-04-12 | 2025-10-16 | Immunic Ag | Synthesis of vidofludimus and its calcium salt |
| CN119979562B (zh) * | 2025-02-28 | 2026-04-17 | 南京农业大学 | 水稻gif4基因在调控籽粒灌浆和粒重中的应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US529490A (en) * | 1894-11-20 | hegg-em | ||
| EP0008532B1 (en) * | 1978-08-22 | 1983-07-20 | Sumitomo Chemical Company, Limited | Synthesis of amines |
| JPH05331163A (ja) * | 1991-03-26 | 1993-12-14 | Kumiai Chem Ind Co Ltd | ピリジン誘導体及び除草剤 |
| DE69429078T2 (de) * | 1993-10-01 | 2002-07-11 | Novartis Ag, Basel | Pharmacologisch wirksame pyridinderivate und verfahren zu deren herstellung |
| PL182198B1 (en) | 1995-06-21 | 2001-11-30 | Asta Medica Ag | Pharmaceutic powder holding container with integrated measuring device and powdered |
| DE19547648A1 (de) | 1995-12-20 | 1997-06-26 | Hoechst Ag | Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate |
| DE19610955A1 (de) | 1996-03-20 | 1997-09-25 | Hoechst Ag | Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid |
| GB9804343D0 (en) | 1998-02-27 | 1998-04-22 | Univ Cardiff | Chemical compounds |
| IL146971A0 (en) * | 1999-06-10 | 2002-08-14 | Warner Lambert Co | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits |
| DK1381356T3 (da) | 2001-04-05 | 2008-09-22 | Aventis Pharma Inc | Anvendelse af (z)-z-cyano-3-hydroxy-but-2-enoinsyre-(4-trifluoromethylphenyl) - amide til behandling af multipel sclerose |
| PE20030120A1 (es) | 2001-06-19 | 2003-02-12 | Merck & Co Inc | Sal amina de un antagonista de receptor de integrin |
| DE10129703A1 (de) | 2001-06-22 | 2003-01-02 | Sofotec Gmbh & Co Kg | Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren |
| MXPA04000224A (es) * | 2001-07-10 | 2005-07-25 | 4Sc Ag | Novedosos compuestos como agentes antiinflamatorios, inmunomoduladores y antiproliferativos. |
| DE10202940A1 (de) | 2002-01-24 | 2003-07-31 | Sofotec Gmbh & Co Kg | Patrone für einen Pulverinhalator |
| US7258118B2 (en) | 2002-01-24 | 2007-08-21 | Sofotec Gmbh & Co, Kg | Pharmaceutical powder cartridge, and inhaler equipped with same |
| AR042206A1 (es) | 2002-11-26 | 2005-06-15 | Novartis Ag | Acidos fenilaceticos y derivados |
| WO2004056746A1 (en) | 2002-12-23 | 2004-07-08 | 4Sc Ag | Cycloalkene dicarboxylic acid compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| WO2004056747A1 (en) * | 2002-12-23 | 2004-07-08 | 4Sc Ag | Dhodh-inhibitors and method for their identification |
| SE0400234D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New compounds, methods for their preparation and use thereof |
| AU2005257862A1 (en) | 2004-05-21 | 2006-01-05 | The Uab Research Foundation | Compositions and methods relating to pyrimidine synthesis inhibitors |
| WO2006022442A1 (ja) * | 2004-08-24 | 2006-03-02 | Santen Pharmaceutical Co., Ltd. | ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体 |
| SG142305A1 (en) | 2004-10-19 | 2008-05-28 | Aventis Pharma Inc | Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'- trifluoromethylphenyl)-amide for treating inflammatory bowel disease |
| ES2444866T3 (es) * | 2004-10-20 | 2014-02-27 | Merck Serono Sa | Derivados de 3-arilamino piridina |
| ES2265276B1 (es) | 2005-05-20 | 2008-02-01 | Laboratorios Almirall S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico. |
| ES2319596B1 (es) | 2006-12-22 | 2010-02-08 | Laboratorios Almirall S.A. | Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico. |
| ATE508108T1 (de) | 2007-02-06 | 2011-05-15 | Chelsea Therapeutics Inc | Neue verbindungen, verfahren zu deren herstellung und deren verwendung |
| UY31272A1 (es) | 2007-08-10 | 2009-01-30 | Almirall Lab | Nuevos derivados de ácido azabifenilaminobenzoico |
| EP2135610A1 (en) | 2008-06-20 | 2009-12-23 | Laboratorios Almirall, S.A. | Combination comprising DHODH inhibitors and methotrexate |
| EP2210615A1 (en) | 2009-01-21 | 2010-07-28 | Almirall, S.A. | Combinations comprising methotrexate and DHODH inhibitors |
| EP2230232A1 (en) | 2009-03-13 | 2010-09-22 | Almirall, S.A. | Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors |
| EP2228367A1 (en) | 2009-03-13 | 2010-09-15 | Almirall, S.A. | Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors |
| EP2239256A1 (en) | 2009-03-13 | 2010-10-13 | Almirall, S.A. | Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor |
| EP2314577A1 (en) | 2009-10-16 | 2011-04-27 | Almirall, S.A. | Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid |
-
2006
- 2006-12-22 ES ES200603250A patent/ES2319596B1/es not_active Withdrawn - After Issue
-
2007
- 2007-12-13 UY UY30794A patent/UY30794A1/es active IP Right Grant
- 2007-12-17 CL CL200703666A patent/CL2007003666A1/es unknown
- 2007-12-17 TW TW096148215A patent/TWI405572B/zh not_active IP Right Cessation
- 2007-12-19 AR ARP070105721A patent/AR064444A1/es active IP Right Grant
- 2007-12-21 NZ NZ577017A patent/NZ577017A/en unknown
- 2007-12-21 ME MEP-2012-104A patent/ME01475B/me unknown
- 2007-12-21 RU RU2009127847/04A patent/RU2469024C2/ru active
- 2007-12-21 AU AU2007338321A patent/AU2007338321B2/en not_active Ceased
- 2007-12-21 JP JP2009541921A patent/JP5318776B2/ja not_active Expired - Fee Related
- 2007-12-21 CN CN200780047756XA patent/CN101589025B/zh active Active
- 2007-12-21 ES ES07866261T patent/ES2389785T3/es active Active
- 2007-12-21 KR KR1020097012714A patent/KR101435233B1/ko not_active Expired - Fee Related
- 2007-12-21 SI SI200731012T patent/SI2121614T1/sl unknown
- 2007-12-21 BR BRPI0717697-0A patent/BRPI0717697B1/pt active IP Right Grant
- 2007-12-21 RS RS20120388A patent/RS52514B/sr unknown
- 2007-12-21 CA CA2674512A patent/CA2674512C/en active Active
- 2007-12-21 PT PT07866261T patent/PT2121614E/pt unknown
- 2007-12-21 PL PL07866261T patent/PL2121614T3/pl unknown
- 2007-12-21 HR HRP20120697TT patent/HRP20120697T1/hr unknown
- 2007-12-21 MY MYPI20092607A patent/MY153393A/en unknown
- 2007-12-21 EP EP07866261A patent/EP2121614B1/en active Active
- 2007-12-21 DK DK07866261.6T patent/DK2121614T3/da active
- 2007-12-21 MX MX2009006408A patent/MX2009006408A/es active IP Right Grant
- 2007-12-21 US US12/520,237 patent/US8258308B2/en active Active
- 2007-12-21 WO PCT/EP2007/011401 patent/WO2008077639A1/en not_active Ceased
-
2008
- 2008-01-02 PE PE2008000062A patent/PE20081846A1/es active IP Right Grant
-
2009
- 2009-05-14 ZA ZA200903333A patent/ZA200903335B/xx unknown
- 2009-06-04 IL IL199188A patent/IL199188A/en active IP Right Grant
- 2009-06-09 EC EC2009009395A patent/ECSP099395A/es unknown
- 2009-06-22 NO NO20092380A patent/NO341991B1/no unknown
-
2012
- 2012-08-06 US US13/567,437 patent/US8691852B2/en not_active Expired - Fee Related
- 2012-09-04 CY CY20121100791T patent/CY1113687T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR064444A1 (es) | Derivados de los acidos amino- nicotinico y amino-isonicotinico. composiciones farmaceuticas | |
| CR10643A (es) | DERIVADOS DE 2-ARIL-6-FENIL-IMIDAZOL[1,2-a]PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA | |
| CO5580746A2 (es) | Derivados de fenil-piperazina como inhibidores de la reabsorcion de la serotonina | |
| ES2530943T3 (es) | Derivados de la cromenona con actividad antitumoral | |
| CO6300864A2 (es) | Derivados polisustituidos de 6-heteroaril-imidazo[1,2-a]piridinas su preparacion y su aplicacion en terapeutica | |
| AR070992A1 (es) | Derivados de 2-aril-6-fenil-inidazo[1,2a]piridinas, su preparacion, composiciones farmaceuticas y su uso en enfermedades que implican los receptores nucleares nurr-1 | |
| AR049784A1 (es) | Derivados sustituidos de morfolina y tiomorfolina | |
| CO6190521A2 (es) | Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta -9 desaturasa | |
| NI201000130A (es) | Derivados de urea de tetrahidroquinoxalina, su preparación y su aplicación en terapéutica. | |
| CU23926B1 (es) | Derivado de oxopirazina y herbicida | |
| ES2192520T3 (es) | Composicion farmaceutica. | |
| CO6290657A2 (es) | Derivados polisustituidos de 2-aril-6-fenil-imidazo[1,2-alfa]piridinas su preparacion y su aplicacion en terapeutica | |
| CO6300867A2 (es) | Derivados polisustituidos de 2 -heteroaril-6-fenil-imidazo[1,2-a]piridinas su preparacion y su aplicacion en terapeutica | |
| CO6321168A2 (es) | Nuevos derivados de 2-amidotiadiazol | |
| AR073043A1 (es) | Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras. | |
| CO6251235A2 (es) | Compuestos derivados de azetidinas su preparacion y su aplicacion en terapeutica | |
| ECSP077215A (es) | Derivados de n-(1h-indolil)-1h-indol-2-carboxamidas, su preparación y su aplicación en terapéutica | |
| NO20062617L (no) | Anvendelse av glukosidase inhibitorer for terapi av mucovisidose | |
| AR050266A1 (es) | Derivados de bencil-triazolona como inhibidores no nucleosidos de transcriptasa inversa | |
| CO5550437A2 (es) | Compuestos quimicos | |
| CO6400145A2 (es) | Derivados de 2-piridin-2-il pirazol-3(2h) -ona, su preparción y su aplicación terapeútica | |
| CO6300944A2 (es) | Derivado de hidroxi-quinoxalin-carboxamida | |
| CO6251285A2 (es) | Derivado de tetrahidroisoquinolina novedoso | |
| NI200600279A (es) | Derivados de tetrahidroisoquinolilsulfonamidas, su preparación y su utilización en terapéutica | |
| AR054583A1 (es) | Pantoprazol isotopicamente sustituido |